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1. Introduction 
Enantioenriched γ-butyrolactones are highly valuable 
compounds displaying a broad biological profile with 
applications as flavor and aroma constituents.
1
 In addition, they 
also possess multiple uses as building blocks for polymers and 
natural product synthesis. As examples, γ-valerolactone is 
recognized as a potential intermediate for the production of 
fuels,
2
 and 4-substituted analogues as precursors of analgesics,
3
 
GABA receptor inhibitors,
4
 and lignans,
5
 a family of compounds 
with broad range of activities including antiviral and 
antineoplastic. 
The selective synthesis of spiro compounds is also highly 
appealing due to their interesting conformational features and 
structural implications on biological systems.
6
 Hence, the spiro 
functionality is known to be present in a variety of 
phytochemicals such alkaloids or terpenoids.
7
 In particular, 
spirolactones are important motifs in medicinal and natural 
product chemistry.
8
 The intrinsic rigidity imparted by the spiro 
center, together with the latent lactone functionality, has been 
postulated as the source of these beneficial activities. 
Among the different strategies to synthesize enantiopure γ-
lactone derivatives, biocatalytic approaches have rapidly gained 
ground due to the excellent selectivities demonstrated by 
enzymes under mild reaction conditions.
9
 Among them, 
hydrolase-catalyzed (dynamic) kinetic resolutions starting from 
the corresponding racemic lactones or hydroxy ester precursors,
10
 
and alcohol dehydrogenase-mediated stereoselective oxidations 
of racemic diols or reductions of keto esters can be cited.
11
 
Alternatively, the use of Baeyer-Villiger monooxygenases 
(BVMOs) to achieve the BV oxidation of racemic or prochiral 
cyclic ketones has also been studied to afford the enantiopure 
products.
12
 This class of oxidoreductases is a promising family of 
biocatalysts able to perform the oxidation of carbonylic 
compounds as well as certain heteroatoms with excellent regio- 
and/or enantioselectivities, by simply using oxygen as final 
electron acceptor while releasing water as the only byproduct.
13
 
Thus, although both kinetic and dynamic kinetic resolutions of 
racemic ketones could also be performed, desymmetrization 
reactions of prochiral substrates represent one of the most 
appealing applications as they allow a theoretical yield of 100% 
of enantiopure products. More specifically, the desymmetrization 
of 3-substituted cyclobutanones via BVMO-catalyzed oxidation 
has been successfully performed to gain access to the 
corresponding enantioenriched γ-butyrolactones.
14
 
As part of our ongoing interest related to the application of 
biological catalysts to obtain valuable compounds, herein we 
show the application of several commercially available BVMOs 
in the desymmetrization of prochiral cyclobutanones (Scheme 1), 
including also interesting spiro derivatives which, to the best of 
our knowledge, have not been previously studied under similar 
biocatalytic oxidative conditions. The optimization of the 
reaction conditions and the scale-up of the biotransformation 
have been considered as well. 
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Scheme 1. General approach to enantioenriched 4-substituted γ-
butyrolactones based on a BVMO-catalyzed desymmetrization 
process. 
 
2. Results and discussion 
Six different Baeyer-Villiger monooxygenases acquired from 
Codexis were studied towards the oxidation of cyclohexanone, a 
typical substrate for BVMOs. An initial enzyme activity 
screening was performed using conditions previously optimized 
in our research group,
15
 which imply a 10 mM substrate 
concentration, use of co-solvent (DMSO, 1% v/v), NADPH (0.2 
mM), glucose (20 mM), glucose dehydrogenase (GDH, 10 U) 
and phosphate buffer 100 mM pH 9. The reactions were initially 
carried out at 30 ºC and 250 rpm for 24 h in a 0.5 mL scale. In 
order to improve the obtained results, some reaction parameters 
were modified. Among them, addition of other prosthetic groups 
(FAD or FMN) and variations in the nicotinamide (NADH 
instead of NADPH), cofactor regeneration systems (glucose-6-
phosphate/glucose-6-phosphate dehydrogenase or sodium 
formate/formate dehydrogenase instead of glucose/glucose 
dehydrogenase), buffer pH (7, 8, 9 or 10) or temperature (20, 30 
or 40 ºC) can be named, but none of them improved the first 
reaction conditions. Remarkably, we noticed the formation of the 
corresponding alcohol at higher temperatures, due to the 
concomitant presence of alcohol dehydrogenase(s) in these 
enzymatic preparations. Interestingly, when different co-solvents 
were explored, better results were observed especially in the 
presence of methanol. For this reason, together with its lower 
boiling point compared to that of dimethylsulfoxide, which 
allows an easier elimination from the reaction media, methanol 
was the co-solvent selected from now on. 
Once the reaction parameters had been optimized, our 
attention was focused on cyclobutanone (1a) for being the 
simplest substrate of the family. It turned to be highly reactive, 
affording conversions up to 98% into the corresponding lactone 
2a as can be seen in Table 1. Additional experiments were 
performed in order to contemplate the possibility of carrying out 
the biotransformations under stirring conditions. Hence, the 
biooxidation of cyclobutanone was performed on a 30 mg scale 
in the presence of BVMO-P1-D-08 using magnetic stirring, 
observing also a complete conversion at either 250 or 900 rpm 
(see conditions in Supporting Information). 
 
 
 
 
 
 
Table 1. Activity of different BVMOs towards cyclobutanone 
(1a).
a 
 
Entry Enzyme c (%)b 
1 BVMO-P1-C06 88 
2 BVMO-P1-D08 98 
3 BVMO-P3-A10 19 
4 BVMO-P3-A12 47 
5 BVMO-P3-C07 52 
6 CDX-003 2 
a Reaction conditions (0.5 mL): Cyclobutanone (10 mM) in phosphate buffer 
100 mM pH 9 with MeOH (1% v/v), NADPH (0.2 mM), glucose (20 mM), 
GDH (10 U) and BVMO (2 mg) for 24 h at 30 ºC and 250 rpm. b Determined 
by GC. 
These promising results inspired us to employ these enzymes 
on useful compounds, as could be the synthesis of a broad family 
of enantioenriched (spiro)lactones starting from the 
corresponding cyclic ketones. To start with, cyclobutanone 
bearing a phenyl group at position 3 (1b)
16
 was selected as model 
prochiral substrate. Under previously optimized conditions, the 
screening of the six BVMOs was thereby performed (Table 2). 
To our delight, a total conversion into the corresponding lactone 
(2b) was achieved in all cases, also reaching excellent 
enantiomeric excess for BVMO-P1-D08 and CDX-003 to obtain 
the (R)-enantiomer (entries 3 and 7). Interestingly, BVMO-P3-
C07 showed an opposite selectivity although at lower extent 
(83% ee, entry 6). A more detailed study demonstrated that 
quantitative conversions were obtained after just 4 h of reaction, 
indicating the stability of the final product in the reaction media. 
For comparison, other previous reports related to BVMO-
catalyzed oxidations on substrate 1b using purified or 
overexpressed enzymes, have been added in Table 2 (entries 8-
19). As can be seen, earlier articles have employed lower 
substrate concentrations affording lactone 2b with moderate to 
high yields and enantiomeric excess. As can be seen, 
cyclohexanone monooxygenases (CHMOs) coming from 
different sources
14e,f,g,h,j
 allowed synthesizing the (R)-enantiomer, 
while other biocatalysts such as steroid monooxygenase (STMO, 
entry 10),
14j
 cyclopentanone monooxygenase (CPMO, entry 
14),
14g
 and 4-hydroxyacetophenone monooxygenase (HAPMO, 
entry 19),
14d
 afforded preferentially (S)-2b. 
  
 3 
Table 2. Oxidation of 3-phenylcyclobutanone (1b) using 
commercial BVMOs.
a 
 
Entry Enzyme 1b concentration (mM) 2b (%)b eeP (%)
c 
1 ----d 10 0 ---- 
2 BVMO-P1-C06 10 >99 11 (R) 
3 BVMO-P1-D08 10 >99 98 (R) 
4 BVMO-P3-A10 10 >99 7 (S) 
5 BVMO-P3-A12 10 >99 53 (S) 
6 BVMO-P3-C07 10 >99 83 (S) 
7 CDX-003 10 >99 97 (R) 
8 CHMOe 5 46 59 (R) 
9 CAMOf 5 71 91 (R) 
10 STMOg 5 72 76 (S) 
11 CHMOh n.f. >90 83 (R) 
12 CHMOi 3 45 93 (R) 
13 CHMOj 3 73 98 (R) 
14 CPMOk 3 66 37 (S) 
15 CHMOl n.f. >90 62 (R) 
16 CHMOm n.f. >90 96 (R) 
17 CHMOn 3 54 87 (R) 
18 CHMOo 3 63 50 (R) 
19 HAPMOp 3 12 92 (S) 
a Reaction conditions (0.5 mL): 1b in phosphate buffer 100 mM pH 9 with 
MeOH (1% v/v), NADPH (0.2 mM), glucose (20 mM), GDH (10 U) and 
BVMO (2 mg) for 24 h at 30 ºC and 250 rpm. b Determined by GC. c 
Determined by HPLC. d Blank reaction with no enzyme. e Cyclohexanone 
monooxygenase from A. calcoaceticus; reference 14j. f Cycloalkanone 
monooxygenase from C. radicicola; reference 14j. g Steroid monooxygenase 
from R. rhodochrous; reference 14j. h Cyclohexanone monooxygenase from 
Xanthobacter sp.; reference 14h. i Cyclohexanone monooxygenase from 
Brachymonas; reference 14g. j Cyclohexanone monooxygenase from 
Brevibacterium, type 1; reference 14g. k Cyclopentanone monooxygenase 
from Comamonas; reference 14g. l Cyclohexanone monooxygenase from 
Acinetobacter sp.; reference 14f. m Cyclohexanone monooxygenase from 
Acinetobacter sp., mutant; reference 14f. n Cyclohexanone monooxygenase 
from Arthrobacter sp.; reference 14e. o Cyclohexanone monooxygenase from 
Rhodococcus; reference 14e. p 4-Hydroxyacetophenone monooxygenase from 
P. fluorescens; reference 14d. n.f.: Not found. 
Prochiral 3-substituted cyclobutanones turned out to be quite 
reactive, most likely related to the liberation of ring-strain upon 
rearrangement and ring expansion. So, at this point, in order to 
enhance the process efficiency and synthetic applicability, we 
attempted to increase the substrate concentration up to 50 mM 
(Figure 1). However, in spite of maintaining the 
enantioselectivity, we came across to a dramatic decrease in the 
enzyme activity as well as the formation of the corresponding 
alcohol in appreciable amount (1-10%). Remarkably, a 73% of 
lactone 2b was reached when the reaction with CDX-003 at 20 
mM was allowed continuing for 48 h. 
 
Figure 1. Evolution of lactone 2b formation using different 
substrate concentration. 
To discard the possibility of enzyme inhibition by the 
substrate, its addition was studied in two portions every 24 h, but 
results were even worse (61%). With the same aim, we also 
performed the biotransformations at 10 mM for 24 h employing a 
biphasic system using 10% v/v of heptane, observing that the 
enzymes were slightly deactivated, reaching high conversions 
(81-97%) and maintaining their enantioselectivity. As pH could 
change in the medium due to higher concentrations of glucose, 
and therefore formation of gluconic acid, we increased the 
strength of the buffer up to 200 mM, but a decrease in the 
enzyme activity was noticed (19% of 2b). Finally, we considered 
the possibility of enzyme deactivation after a certain period of 
time. This problem should be avoided by adding fresh biocatalyst 
after 24 h, but a complete conversion could not be achieved 
either with an initial substrate concentration of 20 mM (84%) or 
the BVMO addition in two parts (74%). 
In this sense, it was also studied the possibility of enzyme 
recycling by means of reusing the aqueous phase after extraction 
with heptane, which does not inhibit the biocatalyst at 10 mM 
substrate concentration (data not shown), but the conversion in 
the second cycle remained below 50%. With these results in 
hand, the strategy was extended to a broad panel of 3-substituted 
cyclobutanones (Figure 2). 
Some of them were commercially available (1f,g,i-k), while 
other were synthesized through conventional chemical protocols 
(1c-e,h,l-o, see Supporting Information). Table 3 summarizes the 
best results found (see the Supporting Information for complete 
data). 
Initially, the influence of different substituents in the phenyl 
ring at position 3 was analyzed (1c-h). Both R- and S-selective 
monooxygenases seemed to act better when they were placed at 
the para position, leading to almost complete conversions and 
high enantiomeric excess into 2e-h (from 86 to 97%, depending 
on both substrate and biocatalyst). The meta-substituted 
compound 1d offered worse results in terms of reactivity and the 
orto-bromo substrate 1c led to lower conversion and 
stereoselectivity values in comparison with the 3-(4’-
bromophenyl)cyclobutanone (1e). For instance, BVMO-P1-D08 
and CDX-003 were able to achieve usually very high conversions 
and ee into the corresponding (R)-lactones, while BVMO-P3-C07 
afforded the best results for para-substituted derivatives in order 
to gain access to the S-antipodes. We then compare our results 
with previous reports using purified or overexpressed BVMOs, 
finding that ketone 1f was formerly studied. Hence, results 
obtained with P3-C07 and CDX-003 were comparable in terms 
of activity and selectivity with biotransformations using various 
CHMOs.
14g,h
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Figure 2. 3-Substituted cyclobutanones subjected to oxidation with commercial BVMOs. 
Table 3. Best results found for BVMO-catalyzed oxidations of prochiral 3-substituted cyclobutanones under optimum conditions.
a 
 
Substrate 
(S)-Lactone  (R)-Lactone 
Ketone 
concentration (mM) 
BVMO Lactone (%)b eeP (%)
c Ketone 
concentration (mM) 
BVMO Lactone (%)b eeP (%)
c 
1c 10 P3-C07 51 87 10 P1-D08 95 (4) 89 
1d 10 P1-C06 79 47 10 CDX-003 43 98 
1e 10 P3-C07 95 (5) 97 10 P1-D08 99 93 
1f 10 P3-C07 95 (2) 94 10 CDX-003 93 96 
 n.f. CHMOd >90 81 2.2 CHMOe 47 87 
 2.2 CHMOf 63 95     
1g 10 P3-C07 94 (4) 86 10 CDX-003 89 (11) 97 
1h 10 P3-C07 99 86 10 CDX-003 98 87 
1ig 10 P1-D08 >99 82 10 P3-C07 >99 77 
1j 10 P1-C06 >99 54 10 P1-D08 >99 79 
 2.4 CHMOe 26 55 2.4 CPMOh 53 63 
 n.f. CHMOi >90 53 n.f. CHMOj >90 83 
 n.f. MO1k 98 74 3 HAPMOl 35 29 
     n.f. MO2m 95 90 
1kg 10 P1-D08 29 (41)n 78 10 P1-C06 46 (43)n 32 
1l 10 P3-A10 >99n 96     
1n 10 P3-C07 98 94 10 P1-D08 >99 93 
1og     10 P3-A10 >99 97 
a Reaction conditions (0.5 mL): 1c-l,n,o in phosphate buffer 100 mM pH 9 with MeOH (1% v/v), NADPH (0.2 mM), glucose (20 mM), GDH (10 U) and BVMO 
(2 mg) for 24 h at 30 ºC and 250 rpm. b Determined by GC analysis (alcohol formation in brackets). c Determined by chiral HPLC analysis. d Cyclohexanone 
monooxygenase from Xanthobacter sp.; reference 14h. e Cyclohexanone monooxygenase from Brevibacterium, type 1; reference 14g. f Cyclohexanone 
monooxygenase from Rhodococcus; reference 14g. g Change in Cahn-Ingold-Prelog (CIP) priority. h Cyclopentanone monooxygenase from Comamonas; 
reference 14g. i Cyclohexanone monooxygenase from Acinetobacter sp.; reference 14f. j Cyclohexanone monooxygenase from Acinetobacter sp., mutant; 
reference 14f. k Monooxygenase from P. putida, type 1; reference 14a. l 4-Hydroxyacetophenone monooxygenase from P. fluorescens; reference 14d. m 
Monooxygenase from P. putida, type 2; reference 14a. n Determined by 1H-RMN. n.f.: Not found. 
 
Then, our interest turned into the study of the behavior of 
these biocatalysts when a heteroatom such as oxygen or nitrogen, 
was introduced at the substituent of the prochiral cyclobutanone. 
On the one hand, oxygenated derivatives 2i and 2j could be 
obtained with BVMO-P3-C07, P1-C06 or P1-D08 with complete 
conversions but with moderate enantiomeric excess [from 54% 
for (S)-2j to 82% for (S)-2i]. In this sense, previous reports 
concerning BVMO-catalyzed oxidations on substrate 1j have 
demonstrated that this substrate is usually converted with 
moderate selectivities.
14a,d,f,g
 On the other hand, nitrogenated 
derivatives 1k and 1l showed several complications. Both 
ketones and lactones revealed solubility problems and also 
displayed very low GC signals. Hence, it was necessary to work 
at a higher scale in order to study the transformations through 
1
H-
NMR technique. When testing substrate 1k, apart from a low 
conversion degree and enantioselectivity, a huge amount of the 
corresponding alcohol was detected, in some cases even higher 
than the lactone of interest. However, when compound 1l was 
treated under the same conditions, complete conversions were 
achieved with all tested enzymes except CDX-003. Remarkably, 
(S)-lactone 2l was formed in quantitative conversion and 96% ee 
using BVMO-P3-A10. 
Additionally, and having in mind its possible synthetic 
applications, we tested the transformation over ethyl ester 1m, 
but only traces of lactone 2m could be detected due to hydrolysis 
of the substrate. We also synthesized the benzyl ester derivative 
seeking a higher stability towards hydrolysis, but similar results 
were found. 
Next, we wondered if the set of Baeyer-Villiger 
monooxygenases could transform compounds bearing quaternary 
centers. With this aim, after synthesizing ketones 1n and 1o (see 
Supporting Information), and subjecting them to enzymatic 
oxidation, we came across with unexpected results. On the one 
hand substrate 1n, with the 3-position quaternized, could be 
transformed into both enantiomers of the corresponding lactone 
either with BVMO-P3-C07 [(S)-2n, 92% conversion and 94% ee] 
or BVMO-P1-D08 [(R)-2n, >99% conversion and 93% ee]. On 
 5 
the other hand substrate 1o, with the quaternary center in an 
adjacent position, in spite of being able to react in a more 
enantioselective way (97% ee) towards the formation of the 
lactone (R)-2o assisted by BVMO-P3-A10, none of the 
biocatalysts in the set catalyzed the formation of the other 
enantiomer (S)-2o. 
Once evaluated the efficiency of the enzyme set with this type 
of substrates, we decided to explore another family with an 
increased degree of complexity, the spiro compounds, with 
potential applications in medicinal chemistry (Figure 3).
17
 
 
Figure 3. Family of spiro compounds subjected to oxidation with 
commercial BVMOs. 
To begin with these unprecedented oxidations, we purchased 
the N-Boc protected compounds 1p-r. To study if these spiro 
derivatives could be appropriate for our BVMOs, achiral 
compound 1p was chosen as model substrate. Thus, employing 
the same conditions previously optimized, we found that only 
BVMO-P3-C07 could afford 90% of the lactone 2p with a 
minimum amount of alcohol formation (5%), while the other 
monooxygenases remained below 80% with an alcohol formation 
up to 37% (see complete data in Supporting Information). In 
order to avoid the generation of such quantity of the reduction 
product, we attempted the use of an organic solvent (10% v/v) 
such as heptane, driving the reaction in a biphasic system, but the 
results were quite similar. The presence of heptane neither 
deterred or improved the activity of the enzyme, nor prevented 
the alcohol formation (data not shown). Then, we carried out the 
study with prochiral N-Boc spiro compounds 1q and 1r. 
Surprisingly, several biocatalysts led to more than 85% lactone 
formation, while only traces of the corresponding alcohol were 
detected (see complete data in Supporting Information). 
However, owing to the lack of a chromophore group, the 
enantiomeric excess of the final products could not be measured. 
For this reason, we decided to introduce other common 
protecting groups for amines, such as benzyloxycarbonyl (Cbz, 
1s and 1t) and benzyl (Bn, 1u and 1v), which are more suitable 
for UV detection (see Supporting Information for detailed 
conditions). 
When 1s and 1t were subjected to BVMO-catalyzed 
transformation in the same conditions, we realized that the effects 
of the enzymes were completely different on each substrate, 
regarding both conversion and selectivity (Table 4). With respect 
to 1s, though in some cases conversions reached were acceptable, 
the enantiomeric excess of the lactones remained low-to-high. It 
can only be outlined the result with BVMO-P3-C07, which led to 
the lactone in 64% conversion and 86% ee with a minimum 
formation of the alcohol product. Regarding 1t it is worth to 
remark that employing BVMO-P3-A10, an excellent conversion 
into lactone 2t with high ee (87%) and only 2% of alcohol, was 
achieved. 
Once benzylated ketones 1u and 1v had been synthesized, we 
realized the complexity of its chemical Baeyer-Villiger oxidation, 
as the product formed under the presence of the peracid was the 
N-oxide derivative (see Supporting Information). However, this 
reason confers additional value to our method employing 
biocatalysis. Thus, when ketone 1u was subjected to enzymatic 
Baeyer-Villiger oxidation in the same conditions (Table 4), no 
product (neither starting material nor lactone) was detected by 
GC with most biocatalysts, probably due to the formation of the 
N-oxide, which remained in the aqueous phase during the 
extraction protocol. Luckily, BVMO-P3-C07 allowed the access 
to lactone 2u with a conversion degree up to 79%, although the 
process proceeded with only moderate enantioselectivity (59% 
ee). Surprisingly, in spite of the N-oxidative competing reaction, 
results obtained with substrate 1v were better, detecting the 
lactone formation in all cases (see complete data in the 
Supporting Information). Remarkably, BVMO-P3-C07 made 
possible the synthesis of lactone 2v after 24 h with 82% 
conversion and 86% ee. Furthermore, BVMO-P1-D08 acted with 
total stereopreference, even though the side reaction still 
remained important. 
Once the general studies came to an end, and aiming at a 
practical application, we thought about the possibility of scaling-
up the process together with a reduction in the enzyme loading. 
In this sense, we handled 15-times higher scale reactions, 
keeping proportions in a linear manner (Figure 4). Initially, under 
identical conditions, we verified that the results could be 
reproduced in Erlenmeyer flasks thermostated at 30 ºC and 250 
rpm. Even when the enzyme loading was reduced by a factor of 
two (2 mg/mL), complete conversions were achieved. However, 
when only 1 mg of enzyme per mL of reaction media was 
employed, it was not enough to transform all starting material 
after 24 h but the selectivity remained unaltered. 
 
 
 
 
Table 4. Best results found for BVMO-catalyzed oxidation of spiro compounds under optimum conditions.
a 
 
Substrate 
(+)-Lactone (–)-Lactone 
BVMO Lactone (%)b eeP (%)
c BVMO Lactone (%)b eeP (%)
c 
1s P3-C07 64 (3) 86 P1-D08 66 (15) 68 
1t P3-C07 36 76 P3-A10 98 (2) 87 
1u P3-C07 79 59 n.f. 
1v P3-C07 82 86 P1-D08 46d >99 
a Reaction conditions (0.5 mL): 1s-v (10 mM) in phosphate buffer 100 mM pH 9 with MeOH (1% v/v), NADPH (0.2 mM), glucose 
(20 mM), GDH (10 U) and BVMO (2 mg) for 24 h at 30 ºC and 250 rpm.  b Determined by GC analysis (alcohol formation in 
brackets). c Determined by chiral HPLC analysis. d Low peak intensity, loss of product in the aqueous phase. n.f.: Not found. 
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Figure 4. Optimization of the enzyme loading in 15x-scale 
biotransformations of 1b with BVMO-CDX-003. 
At this point, several selected Baeyer-Villiger oxidation 
reactions were scaled up to 100 mg employing half as much 
enzyme as in the screening protocols (Table 5 and Table S22), 
demonstrating the applicability of the process as almost complete 
conversions were reached for most of the studied substrates, and 
the stereoselectivity of the processes remained very similar. 
Furthermore, the enantioenriched pure lactones could be easily 
recovered after a simple extraction protocol when all starting 
material was consumed. In other cases, purification through 
column chromatography was necessary. 
Table 5. Scale-up in the lactonization reaction of selected 
ketones.
a
 
Substrate BVMO Lactone (%)a Alcohol (%)b eeP (%)
c 
1b P3-C07 81 19 82 (S) 
CDX-003 97 (90) 0 93 (R) 
1n P3-C07 87 0 94 (S) 
P1-D08 >99 (89) 0 92 (R) 
1s P3-C07 93 (77) 0 87 (+) 
1t P3-A10 99 (93) 0 86 (–) 
a Reaction conditions: 1b,n,s,t (100 mg, 10 mM) in phosphate buffer 100 mM 
pH 9 with MeOH (1% v/v), NADPH (0.2 mM), glucose (20 mM), GDH 
(1250 U) and BVMO (2 mg/mL) for 24 h at 30 ºC and 250 rpm. b Determined 
by GC analysis (isolated yields in brackets). c Determined by chiral HPLC 
analysis. 
3. Conclusions 
In summary, a series of commercially available BVMOs have 
been identified as efficient catalysts for the synthesis of 
enantioenriched lactones through desymmetrization of prochiral 
3-substituted cyclobutanones. Thus, both enantiomers of several 
γ-butyrolactones could be obtained in many cases with high or 
excellent conversions and selectivities. These derivatives are 
highly important as they have found many applications in 
different fields as pharmaceuticals and fuel or polymer 
precursors, among others. While enzymatic (dynamic) kinetic 
resolutions of racemic lactones or hydroxy ester derivatives have 
offered interesting results, the desymmetrization of a prochiral 
precursor is an appealing process as it can give access to 
quantitative yield of an enantiopure product in the best case. 
Herein, starting from various ketones and after optimization of 
the enzymatic reaction conditions, it has been demonstrated that 
several enzymatic preparations could be employed to efficiently 
synthesize chiral γ-butyrolactones substituted at the 4-position, 
comprising aromatic rings, (hetero)alkyl chains, and also spiranic 
compounds. In fact, to the best of our knowledge, this is the first 
report related to a biocatalytic process to get access to such 
heterocyclic derivatives. To obtain the (S)-enantiomers, BVMO-
P3-C07 and BVMO-P1-C06 usually offered the best results, 
while for getting the (R)-antipodes, BVMO-P1-D08 and CDX-
003 showed the best performances. These transformations show 
similar, or even better, performances that previous reports with 
these cyclobutanones in terms of activity and selectivity,
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 the 
possibility to carry out the biotransformations being practical at a 
higher substrate concentration. 
It is noteworthy that when the ketone substrate was not well 
accepted by the BVMO, the corresponding alcohol was detected 
at some extent, probably due to the undesired presence of alcohol 
dehydrogenases in these preparations. In some cases biphasic 
systems were tested to improve conversions, and although 
enzyme inactivation was not observed at high extent, results 
could not be improved. Finally, efforts were focused on the scale-
up of some of the biocatalytic oxidations, showing that reactions 
on a 100 mg scale could be easily carried out reducing the 
quantity of enzyme employed at smaller scale to obtain similar 
conversion and ee values. This study demonstrates a new 
sustainable alternative to produce interesting lactones which are 
not easily accessible by other conventional chemical methods. 
4. Experimental part 
4.1. General procedures 
Chemicals and cyclobutanones 1a,f,g,i-k,p-r were purchased 
from different commercial sources and were of the highest purity 
available. Baeyer-Villiger monooxygenases and glucose 
dehydrogenase (GDH-105) were acquired from Codexis. Diethyl 
ether and tetrahydrofuran used in chemical transformations were 
previously dried over sodium under inert atmosphere using 
benzophenone as indicator. Phosphoryl chloride (POCl3) was 
distilled under reduced pressure before its utilization. The rest of 
reagents and solvents were employed without additional 
purification. 
Chemical reactions were monitored by analytical TLC, 
performed on silica gel 60 F254 plates, and visualized by UV or 
revealed in a solution of potassium permanganate (1% KMnO4, 
5% K2CO3 and 5% NaOH in water) or p-anisaldehyde (2.5% p-
anisaldehyde, 1% H2SO4 and 1% AcOH in ethanol). Flash 
chromatography was performed using silica gel 60 (230-400 
mesh). IR spectra were recorded on an infrared Fourier transform 
spectrophotometer on NaCl pellets. NMR spectra were recorded 
at 300.13 (
1
H), and 75.5 (
13
C) MHz. The chemical shifts (δ) are 
reported in parts per million (ppm) relative to the solvent residual 
signals and the coupling constants (J) in Hertz (Hz). ESI-TOF 
mode was used to record high-resolution mass spectra (HRMS). 
Gas chromatography (GC) analyses were performed on a 
standard gas chromatograph equipped with a FID. HPLC 
analyses were performed using a standard HPLC chromatograph 
with UV detection. Optical rotations were measured using a 
standard polarimeter with a sodium lamp (D) and are reported in 
units of 10
−1
 deg cm
2
 g
−1
. Melting points were taken on samples 
in open capillary tubes and are uncorrected. 
4.2. General method for the preparation of lactones 2b-t 
To an ice-cooled solution of the corresponding cyclobutanone 
1b-t (0.25 mmol) in dichloromethane (1.0 mL), m-
chloroperbenzoic acid (MCPBA, 88 mg, 0.50 mmol) was added, 
and the resulting mixture stirred for 20 h at room temperature. 
Then, more dichloromethane was added (5 mL) and the solution 
washed repeatedly with a saturated aqueous solution of sodium 
bicarbonate (6×5 mL). The resulting organic phase was dried 
over anhydrous sodium sulfate, filtered and the solvent 
evaporated under reduced pressure. Purification by column 
chromatography on silica gel (10-30% EtOAc/hexane) afforded 
 7 
lactones 2b-t in 38-99% yield (83% for 2b; 72% for 2c; 99% for 
2d; 85% for 2e; 86% for 2f; 88% for 2g; 44% for 2h; 96% for 2i; 
77% for 2m; see below for 2j-l,n-t).
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4.2.1. 4-((Benzyloxy)methyl)dihydrofuran-2(3H)-one (2j). 
58% yield; yellow oil; IR (NaCl) ν 3061, 2913, 2859, 1777, 
1495, 1479, 1454, 1421, 1366, 1266, 1174, 1101, 1023, 736 cm
-1
; 
1
H-NMR (300.13 MHz, CDCl3)  2.37 (dd, 
3
J = 6.3 Hz, 
2
J = 17.7 
Hz, 1H, CHH), 2.61 (dd, 
3
J = 8.9 Hz, 
2
J = 17.7 Hz, 1H, CHH), 
2.77-2.91 (m, 1H, CH), 3.45-3.52 (m, 2H, CHCH2O), 4.18 (dd, 
3
J 
= 5.5 Hz, 
2
J = 9.2 Hz, 1H, OCHH), 4.40 (dd, 
3
J = 7.5 Hz, 
2
J = 9.2 
Hz, 1H, OCHH), 4.53 (s, 2H, OCH2Ph), 7.27-7.39 (m, 5H, Ph); 
13
C-NMR (75.5 MHz, CDCl3):  31.3 (CH2), 35.6 (CH), 70.5, 
70.9 (OCH2, CHCH2O), 73.5 (OCH2Ph), 127.8 (2 CH Ar), 128.0 
(CH Ar), 128.7 (2 CH Ar), 137.8 (Cipso), 176.9 (COO); HRMS 
(ESI
+
, m/z): calcd for C12H15O3 [(M+H)
+
]: 207.1016, found: 
207.1007. 
4.2.2. Benzyl (5-oxotetrahydrofuran-3-yl)carbamate (2k). 
43% yield; white solid; mp: 104-105 ºC; IR (NaCl) ν 3055, 2987, 
1786, 1723, 1514, 1422, 1170, 1066, 1016 cm
-1
; 
1
H-NMR 
(300.13 MHz, CDCl3)  2.43 (dd, 
3
J = 2.9 Hz, 
2
J = 17.8 Hz, 1H, 
CHH), 2.74 (dd, 
3
J = 7.8 Hz, 
2
J = 17.8 Hz, 1H, CHH), 4.16-4.19 
(m, 1H, OCHH), 4.38-4.49 (m, 2H, OCHH + CH), 5.07 (s, 2H, 
OCH2Ph), 5.84 (br d, 
3
J = 3.6 Hz, 1H, NH), 7.28-7.37 (m, 5H, 
Ph); 
13
C-NMR (75.5 MHz, CDCl3):  34.8 (CH2), 48.0 (CH), 
67.2 (OCH2Ph), 73.7 (OCH2), 128.2 (2 CH Ar), 128.4 (CH Ar), 
128.6 (2 CH Ar), 136.0 (Cipso), 155.9 (NCOO), 175.6 (COO); 
HRMS (ESI
+
, m/z): calcd for C12H14NO4 [(M+H)
+
]: 236.0917, 
found: 236.0897. 
4.2.3. Benzyl ((5-oxotetrahydrofuran-3-yl)methyl)carbamate 
(2l). 38% yield; colorless oil; IR (NaCl) ν 3338, 3063, 3033, 
2929, 1773, 1701, 1534, 1454, 1417, 1376, 1254, 1174, 1019, 
738 cm
-1
; 
1
H-NMR (300.13 MHz, CDCl3)  2.25-2.33 (m, 1H, 
CHH), 2.55-2.64 (m, 1H, CHH), 2.76-2.82 (m, 1H, CH), 3.24-
3.28 (m, 2H, CH2NH), 4.05-4.15 (m, 1H, OCHH), 4.33-4.39 (m, 
1H, OCHH), 5.09 (s, 2H, OCH2Ph), 5.21 (br s, 1H, NH), 7.29-
7.42 (m, 5H, Ph); 
13
C-NMR (75.5 MHz, CDCl3):  32.1 (CH2), 
36.0 (CH), 43.0 (CH2NH), 67.2 (OCH2Ph), 71.0 (OCH2), 128.3 
(2 CH Ar), 128.4 (CH Ar), 128.7 (2 CH Ar), 136.2 (Cipso), 156.8 
(NCOO), 176.6 (COO); HRMS (ESI
+
, m/z): calcd for 
C13H15NNaO4 [(M+Na)
+
]: 272.0893, found: 272.0889. 
4.2.4. 4-Methyl-4-phenyldihydrofuran-2(3H)-one (2n): 93% 
yield; White solid; Mp: 49-51ºC; IR (nujol) 3024, 2969, 2930, 
2904, 1773, 1601, 1497, 1305, 1173,1094, 1020, 767 cm
−1
;
1
H-
NMR (300.13 MHz, CDCl3)  1.54 (s, 3H, CH3), 2.68 (dd, 
2
J = 
16.8, 
4
J = 0.4, 1H, CHH), 2.93 (dd, 
2
J = 16.8, 
4
J = 0.6, 1H, 
CHH), 4.39-4.47 (m, 2H, OCH2), 7.18-7.23 (m, 2H, Ph), 7.27-
7.33 (m, 1H, Ph), 7.36-7.42 (m, 2H, Ph); 
13
C-NMR (75.5 MHz, 
CDCl3) 28.1 (CH3), 42.1 (CH2), 44.2 (C), 78.5 (OCH2), 125.2 
(2CH), 127.3 (CH), 129.1 (2CH), 144.4 (C), 176.2 (CO); HRMS 
(ESI
+
, m/z): calcd for C11H12NaO2 [(M+Na)
+
]: 199.0730, found: 
199.0781. 
4.2.5. 4-(2-(Benzyloxy)propan-2-yl)dihydrofuran-2(3H)-one 
(2o): 75% yield; pale yellow oil; IR (NaCl) ν 3055, 2986, 1775, 
1422, 1180, 1026, 706 cm
-1
; 
1
H-NMR (300.13 MHz, CDCl3)  
1.26, 1.27 (2 s, 6H, 2 CH3), 2.44-2.54 (m, 1H, CHH), 2.65-2.77 
(m, 3H, CHH + CH), 4.32-4.43 (m, 2H, OCH2), 4.46 (s, 2H, 
OCH2Ph), 7.25-7.37 (m, 5H, Ph); 
13
C-NMR (75.5 MHz, CDCl3): 
 23.0, 23.3 (2 CH3), 29.7 (CH2), 46.1 (CH), 63.9 (OCH2Ph), 
69.2 (OCH2), 74.2 (CMe2), 127.1 (2 CH Ar), 127.5 (CH Ar), 
128.5 (2 CH Ar), 139.1 (Cipso), 177.5 (COO); HRMS (ESI
+
, m/z): 
calcd for C14H19O3 [(M+H)
+
]: 235.1329, found: 235.1329. 
4.2.6. tert-butyl 7-oxo-6-oxa-2-azaspiro[3.4]octane-2-
carboxylate (2p): 57% yield; white solid; mp: 154-155 ºC; IR 
(NaCl) ν 2977, 2880, 1786, 1692, 1470, 1406, 1366, 1323, 
1286, 1250, 1165, 1150, 1097, 1023, 1016 cm
-1
; 
1
H-NMR 
(300.13 MHz, CDCl3)  1.44 (s, 9H, 
t
Bu), 2.76 (s, 2H, H-8), AB 
system (AB
2
JAB= 8.9 Hz, 4H, H-1 and H-3), 4.40 
(s, 2H, H-5); 
13
C-NMR (75.5 MHz, CDCl3):  28.4 (3C, C-11), 
37.3 (C-4), 39.3 (C-8), 59.0 (C-1 and C-3), 77.4 (C-5), 80.5 (C-
10), 156.0 (NCOO), 174.8 (COO); HRMS (ESI
+
, m/z): calcd for 
C11H17NNaO4 [(M+H)
+
]: 250.1050, found: 250.1097. 
4.2.7. tert-Butyl 3-oxo-2-oxa-7-azaspiro[4.4]nonane-7-
carboxylate (2q): 71% yield; white solid; mp: 65-67 ºC; IR 
(KBr) ν 1782, 1691, 1483, 1463, 1402, 1362, 1307, 1261, 1233, 
1172, 1152, 1120, 1088, 1026, 1018, 854, 775 cm
-1
; 
1
H-NMR 
(300.13 MHz, CDCl3)  1.45 (s, 9H, 
t
Bu), 1.93-1.98 (m, 2H, H-
9), 2.46-2.61 (m, 2H, H-4), 3.37-3.46 (m, 4H, H-6 and H-8), AB 
system (AB
2
JAB= 9.2 Hz, 2H, H-1); 
13
C-NMR 
(75.5 MHz, CDCl3):  28.5 (3C, C-12), 34.5, 35.6 (C-9), 38.7 (C-
4), 44.5, 44.8 (C-8), 45.6, 46.5 (C-5), 54.2, 55.0 (C-6), 75.9 (C-
1), 80.1 (C-11), 154.4 (NCOO), 175.4 (COO) (presence of 
rotamers); HRMS (ESI
+
, m/z): calcd for C12H19NNaO4 
[(M+Na)
+
]: 264.1206, found: 264.1201. 
4.2.8. tert-Butyl 3-oxo-2-oxa-7-azaspiro[4.5]decane-7-
carboxylate (2r): 63% yield; colorless oil; IR (NaCl) ν 3059, 
3026, 2958, 2921, 1785, 1602, 1496, 1445, 1381, 1080, 764 cm
-1
; 
1
H-NMR (300.13 MHz, CDCl3)  1.44 (s, 9H, 
t
Bu), 1.60-1.65 (m, 
2H, H-9), 1.67-1.69 (m, 2H, H-10), AB system 
(AB
2
JAB= 17.6 Hz, 2H, H-4), 3.34-3.40 (m, 4H, 
H-6 and H-8), 3.96 (d, 
2
J = 9.3 Hz, 1H, H-1), 4.11 (d, 
2
J = 9.3 
Hz, 1H, H-1); 
13
C-NMR (75.5 MHz, CDCl3):  22.5 (C-9), 28.5 
(3C, C-13), 33.8 (C-10), 38.6 (C-4), 40.4 (C-5), 43.5 (C-8), 51.2 
(C-8), 75.4 (C-1), 80.4 (C-12), 154.7 (NCOO), 175.9 (COO); 
HRMS (ESI
+
, m/z): calcd for C13H21NNaO4 [(M+Na)
+
]: 
278.1363, found: 278.1360. 
4.2.9. Benzyl 3-oxo-2-oxa-7-azaspiro[4.4]nonane-7-
carboxylate (2s): 58% yield; colorless oil; []D
20
= +11.6 (c 1, 
CHCl3); IR (NaCl) ν 3054, 2984, 2889, 1782, 1701, 1420, 1361, 
1267, 1170, 1109, 1029, 736 cm
-1
; 
1
H-NMR (300.13 MHz, 
CDCl3)  1.97-2.04 (m, 2H, H-9), 2.41-2.63 (m, 2H, H-4), 3.41-
3.58 (m, 4H, H-6 and H-8), 4.11-4.23 (m, 2H, H-1), 5.13 (s, 2H, 
H-11), 7.32-7.38 (m, 5H, Ph); 
13
C-NMR (75.5 MHz, CDCl3):  
34.5, 35.6 (C-9), 38.6 (C-4), 44.7, 45.1 (C-8), 45.7, 46.6 (C-5), 
54.7 (C-6), 67.3 (C-11), 75.8 (C-1), 128.2, 128.3, 128.7 (5C, Ph), 
136.5 (Cipso), 154.8 (NCOO), 175.2 (COO) (presence of 
rotamers); HRMS (ESI
+
, m/z): calcd for C15H17NNaO4 
[(M+Na)
+
]: 298.1050, found: 298.1079. 
4.2.10. Benzyl 3-oxo-2-oxa-7-azaspiro[4.5]decane-7-
carboxylate (2t): 51% yield; pale yellow oil; []D
20
= −32.0 (c 1, 
CHCl3); IR (NaCl) ν 2936, 2860, 1777, 1698, 1470, 1433, 1365, 
1349, 1255, 1238, 1217, 1176, 1101, 1028, 763, 737 cm
-1
; 
1
H-
NMR (300.13 MHz, CDCl3)  1.53-1.61 (m, 2H, H-9), 1.67-1.71 
(m, 2H, H-10), 2.27-2.45 (m, 2H, H-4), 3.35-3.55 (m, 4H, H-6 
and H-8), 4.08-4.15 (m, 2H, H-1), 5.13 (s, 2H, H-12), 7.28-7.40 
(m, 5H, Ph); 
13
C-NMR (75.5 MHz, CDCl3):  22.4 (C-9), 33.7 
(C-10), 38.6 (C-4), 40.2 (C-5), 44.0 (C-8), 51.2 (C-6), 67.6 (C-
12), 75.2 (C-1), 128.1 (2 CH Ar), 128.3 (CH Ar), 128.7 (2 CH 
Ar), 136.5 (Cipso), 155.4 (NCOO), 175.7 (COO); HRMS (ESI
+
, 
m/z): calcd for C16H20NO4 [(M+H)
+
]: 290.1387, found: 290.1394. 
4.3. Alternative method for the preparation of lactones 2u 
and 2v 
Owing to the availability of the free electron pair in the 
nitrogen atoms in substrates 1u,v, the treatment with MCPBA led 
to their N-oxidation. In order to circumvent this problem, a 
partial solution for the synthesis of 2v was found in the use of 
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Oxone
®
 (2KHSO5.KHSO4.K2SO4, potassium 
peroxomonosulfate) as oxidizing agent. Unfortunately, 2u could 
not be synthesized. 
Thus, Oxone
®
 (17 mg, 0.06 mmol) was added over a solution 
of the ketone 1v (10 mg, 0.04 mmol) in a mixture of acetonitrile 
and water (10:1, 0.1 M) and stirred at room temperature for 36 h. 
Then, the solvents were evaporated and the product purified by 
column chromatography on silica gel (2-5% MeOH/CH2Cl2), 
affording lactone 2v in 33% yield. 
7-Benzyl-2-oxa-7-azaspiro[4.5]decan-3-one (2v). Yellow oil; 
IR (NaCl) ν 3054, 2931, 1774, 1453, 1421, 1377, 1352, 1180, 
1158, 1075, 1019, 739 cm
-1
; 
1
H-NMR (300.13 MHz, CDCl3)  
1.25-1.68 (m, 4H, H-9 and H-10), 2.17-2.53 (m, 6H, H-4, H-6 
and H-8), 3.44-3.54 (m, 2H, H-11), 4.04 (d, 
2
J = 9.1 Hz, 1H, H-
1), 4.20-4.23 (m, 1H, H-1), 7.23-7.31 (m, 5H, Ph); 
13
C-NMR 
(75.5 MHz, CDCl3):  22.9 (C-9), 33.8 (C-10), 39.9 (C-4), 40.4 
(C-5), 53.5 (C-8), 61.4 (C-6), 63.0 (C-11), 76.7 (C-1), 127.4 (CH 
Ar), 128.5 (2 CH Ar), 128.9 (2 CH Ar), 138.3 (Cipso), 176.9 
(COO); HRMS (ESI
+
, m/z): calcd for C15H19NNaO2 [(M+Na)
+
]: 
268.1308, found: 268.1326. 
4.4. Enzymatic procedures 
4.4.1. General procedure for the BVMO-catalyzed oxidation 
of prochiral cyclobutanones 1a-j, m-v 
In a typical experiment carried out in 1.5 mL tubes (total 
volume of 500 µL), the substrate 1a-j, m-v (10 mM) was 
dissolved in methanol (5 µL, 1% v/v) and KPi buffer (100 mM, 
pH 9.0, 482 µL), containing glucose (20 mM), glucose 
dehydrogenase (GDH-105, 10 U, from stock solution of 1.275 
U/µL), NADPH (0.2 mM, from a 20 mM stock solution) and the 
corresponding Baeyer-Villiger monooxygenase (2 mg). The 
mixture was shaken at 250 rpm at 30 ºC for 24 h. The reaction 
was stopped by extracting with diethyl ether (2×400 µL) and 
centrifuged at 13000 rpm in order to separate both phases and 
pellet the suspended protein. The organic phases were combined, 
dried over anhydrous sodium sulfate and analyzed by GC in 
order to determine the conversion values. Then, the solvent in 
GC samples was evaporated with a continuous flow of nitrogen, 
the residue re-dissolved in a mixture of hexane:ethanol 90:10 and 
the new sample filtered and analyzed by HPLC, leading to the 
measurement of the enantiomeric excess of the lactones. Control 
experiments in the absence of enzyme were performed for all 
substrates, not observing any reaction product after similar 
periods of time (Tables S1-S19). 
4.4.2. Alternative procedure for the BVMO-catalyzed 
oxidation of prochiral cyclobutanones 1k and 1l 
Owing to the problems that both ketones 1k,l and their 
corresponding lactones 2k,l showed when analyzed by GC, as 
well as their poor solubility in diethyl ether or ethyl acetate, their 
enzymatic transformations were carried out in a bigger scale (×3, 
2 mL tubes) but maintaining identical reaction conditions. After 
24 h, products were extracted with deuterated chloroform (2×400 
µL). The organic phases were dried over anhydrous sodium 
sulfate, filtered and conversion values were determined by 
1
H-
NMR experiments. Similarly, samples were evaporated and the 
residue re-dissolved in a mixture of hexane:ethanol 90:10 for 
HPLC analyses (see Tables S20-S21). 
4.4.3. Procedure for the BVMO-catalyzed oxidation at 100 
mg scale of cyclobutanontes 1b, 1n, 1s and 1t 
Prochiral ketones 1b, 1n, 1s or 1t (100 mg, 10 mM) were 
dissolved in methanol (1% v/v) and KPi buffer (100 mM, pH 
9.0), containing glucose (20 mM), glucose dehydrogenase (GDH-
105, 1250 U), NADPH (0.2 mM) and the corresponding Baeyer-
Villiger monooxygenase (2 mg/mL). The suspensions were 
placed in Erlenmeyer flasks and shaken at 250 rpm in an orbital 
shaker at 30 ºC for 24 h. 1 mL aliquots were taken for conversion 
and enantiomeric excess analysis (same treatment previously 
described). The reactions were stopped by removing the solid 
protein through decantation and extracting the aqueous phase 
with diethyl ether (3×50 µL). The organic fractions were 
combined, dried over anhydrous sodium sulfate, filtered and 
evaporated under reduced pressure affording pure lactones when 
total conversion were achieved. When some starting product 
remained, an additional purification by column chromatography 
in silica gel was needed (50-100% EtOAc/hexane). 
4.4.4. Procedure for the enzyme-catalyzed Baeyer-Villiger 
oxidation of cyclobutanone (1a) using magnetic stirring 
In order to check whether mechanical stirring can influence 
the BVMO activity, cyclobutanone (1a, 30 mg, 10 mM) was 
dissolved in methanol (428 µL, 1% v/v) and KPi buffer (42.4 
mL, 100 mM, pH 9.0), containing glucose (154 mg, 20 mM). 
Then, NADPH (7.1 mg, 0.2 mM), glucose dehydrogenase (GDH-
105, 850 U) and BVMO-P1-D08 (86 mg, 2 mg/mL) were 
subsequently supplemented. The mixture was placed in a 250 mL 
round-bottom flask and shaken at 30 ºC at either 250 or 900 rpm 
with a magnetic stir bar for 24 h. After this time, complete 
conversions were achieved as demonstrated by GC analysis. 
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